氟伏沙明与氯丙米嗪治疗强迫症对照研究  

A control study of fluvoxamine vs.clomipramine in the treatment of obsessive-compulsive disorder

作　　者：李红远 刘富会 刘传芝 李瑞雪 

机构地区：[1]南阳市第四人民医院,河南南阳473000

出　　处：《临床心身疾病杂志》2007年第3期224-225,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨氟伏沙明与氯丙咪嗪治疗强迫症的临床疗效及安全性。方法将40例强迫症患者随机分为研究组和对照组各20例,分别给予氟伏沙明、氯丙咪嗪治疗,观察8w。于治疗前及治疗4w、8w末采用Yale-Brown强迫量表,副反应量表评定临床疗效和不良反应。结果治疗8w末研究组有效率75%,对照组为70%,两组无显著性差异(P>0.05)。Yale-Brown强迫量表评分治疗4w、8w末两组均较治疗前有极显著下降(P均<0.01),同期组间比较均无显著性差异(P均>0.05)。研究组不良反应发生率较对照组低,且程度轻微。结论氟伏沙明治疗强迫症疗效与氯丙米嗪相当,安全性高,依从性好。Objective To explore the clinical efficacy and safety of fluvoxamine vs. clomipramine in obsessive-compulsive disorder（OCD）. Methods 40 patients with OCD were randomly divided into research group （n=20, took fluvoxamine） and control group （n=20, did clomipramine） for 8 weeks. Curative effects were assessed with Yale-Brown Obsessive Compulsive Scale（Y-BOCS） and adverse reactions with the Treatment Emergent Symptoms Scale（TESS） before treatment and at the ends of the 4th and 8th week treatment. Results Effective rates were 75% in the research group and 70% in the control respectively, which showed no significant difference（P〉0.05）. At the ends of the 4th and 8th week score of the Y- BOCS decreased very significantly in both groups compared with pre-treatment（both P〈0.01）, there was no significant difference in synchronization intra-group comparison（both P〉0.05）. The research group had lower incidence of adverse reactions than the control group did, and adverse reactions of the former were little. Conclusion Fluvoxamine has therapeutic equivalence to clomipramine, higher safety and better compliance.

关 键 词：氟伏沙明 氯丙米嗪 强迫症 

分 类 号：R749.79[医药卫生—神经病学与精神病学]